Tim,
TP raises an interesting point about those BTG trials and has pointed out the error in that article. At first glance the BTG trials appear to be mainly regarding HCC, that is the primary liver cancer endemic in Asia and mainly caused by hepatitis infection, rather than MCC, the secondary metastatic form much more common in the richer (?) western countries.
Will try to wade through the BTG trial info.
In the US at present MCC is the dominant contributor to SRX sales with SRX having full FDA approval and BTG not yet fully approved there.
regards, EB
SRX Price at posting:
$28.95 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
